News
Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for atopic dermatitis, asthma, and more. It works to treat those conditions by blocking proteins that cause ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD ...
18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback